Introduction {#s0001}
============

Oncogenic mutations in the epidermal growth factor receptor (EGFR) gene serve as important predictive biomarkers in the non-small cell lung cancer (NSCLC). Most of these mutations commonly occur as in-frame deletions, insertions, or point mutations within exons 18--21 consisted of the kinase domain in *EGFR* and confer constitutive activity and sensitivity to EGFR tyrosine kinase inhibitors (TKIs).[@cit0001] For *EGFR* wild-type patients, EGFR-TKIs still had a low ORR (1--9%).[@cit0002] Uncommon *EGFR* mutation may be existing in these wild-type patients. Currently, next-generation sequencing (NGS) emerged as a new diagnostic approach for detection, more and more rare or atypical *EGFR* mutations have been identified. *EGFR* fusions are detected which are rare events in NSCLC.[@cit0003] Several *EGFR* fusion partner genes have been reported, including RAD51 recombinase gene (*RAD51*), purine-rich element binding protein B gene (*PURB*), tensin 3 gene (*TNS3*), zinc ﬁnger CCHC-type containing 6 gene (*ZCCHC6*) and septin 14 gene (*SEPTIN14*) in NSCLC, most commonly *EGFR*-*RAD51*.[@cit0003]--[@cit0006] Herein, we reported for the first time, the presence of *EGFR* fusion, kinesin family member 5B (*KIF5B*)-*EGFR* in NSCLC. Moreover, we have demonstrated that the patient experienced a remarkable response to EGFR-TKIs. Institutional approval was required to publish the case details. The informed consent was obtained from the patient prior to study commencement and the patient provided informed consent to have their case details, and accompanying images, published. The case report was approved by the ethics committee of Ningbo Medical Center Lihuili Hospital.

Case Report {#s0002}
===========

A 45-year-old Chinese woman presented with half a month history of cough and expectoration to our hospital in May 2019. Physical examinations were unremarkable. No obvious abnormalities were found in laboratory tests, including blood routine, serum biochemistry and tumor biomarkers. A computed tomography (CT) scan of the chest on May 25 revealed a high-density shadow in inferior lobe of right lung ([Figure 1A](#f0001){ref-type="fig"}). The enhanced CT was performed after 2 weeks' treatment with oral moxifloxacin on June 7, which revealed a little progress of the lesion ([Figure 1B](#f0001){ref-type="fig"}). The patient underwent bronchoscopy and aspergillus fumigatus was detected in bronchoalveolar lavage fluid. Therefore, the patient was treated with oral voriconazole (200mg q12h) for more than 1 months. However, the patient's symptoms worsened. The re-checked CT on July 27 demonstrated marked progression of the lesion in inferior lobe of right lung ([Figure 1C](#f0001){ref-type="fig"}) and a new lesion of ground grass opacity (GGO) was also found in the lower left lobe ([Figure 1D](#f0001){ref-type="fig"}). Then, voriconazole treatment was discontinued and the patient underwent CT-guided percutaneous lung biopsy and pathological results showed lung adenocarcinoma ([Figure 2](#f0002){ref-type="fig"}). The tumor tissue was subjected to next-generation sequencing (NGS), using a commercial gene panel targeting 168 cancer-related genes (Burning Rock Biotech Ltd, Guangzhou, China). The NGS reports revealed the *KIF5B*-*EGFR*, a novel rearrangement of the EGFR gene that has not been reported previously ([Figure 3](#f0003){ref-type="fig"}). The patient began treatment with afatinib (40mg qd po) and bevacizumab (400mg q3w ivgtt) since August 14. She experienced sustained clinical improvement after anti-tumor therapy and a CT scan on October 13 revealed marked decrease of the infiltrations on the lower right lung ([Figure 1E](#f0001){ref-type="fig"}) and the absence of GGO on the left lung, assessed as partial remission. The patient had mild rash and diarrhea during treatment, which was considered an adverse reaction associated with EGFR-TKI. Encouragingly, the lesion on the right lower lung continued to shrink during the treatment ([Figure 1F](#f0001){ref-type="fig"}--[H](#f0001){ref-type="fig"}). Thus far, the patient feels well and the disease has remained stable. She has been continuing treatment with afatinib and bevacizumab and will be followed up regularly.Figure 1Computed tomography (CT) images of the patient during the whole diagnosis and treatment procedure. (**A**) CT images showing the infiltrations on the lower right lung at the patient's first visit on May 25; (**B**) CT images on June 7 showing a slightly progressed lesion on the lower right lung after moxifloxacin treatment. (**C**) CT images on July 27 showing marked progressed lesion on the lower right lung after voriconazole treatment. (**D**) CT images on July 27 showing a new ground grass opacity on the lower left lung. (**E**) CT images showing a significant reduced lesion on the lower right lung after 2 months of anti-tumor therapy. (**F**) CT images showed that the lesion on right lower lung continued to shrink after 4 months of anti-tumor therapy. (**G**) CT images showed that the lesion on right lower lung was reduced further after 7 months of anti-tumor therapy. (**H**) CT images showed that only a few ground glass shadows and fibrous lesions remained on the right lower lung after 10 months of anti-tumor therapy.Figure 2Pathological results of tissue obtained through CT-guided percutaneous lung biopsy showing adenocarcinoma (hematoxylin and eosin; magniﬁcation ×200).Figure 3Integrative Genomics Viewer snapshot of EGFR-KIF5B fusion.

Discussion {#s0003}
==========

In clinical practice, *EGFR* fusions are rare in NSCLC. Previously, *EGFR* fusions were observed in large cohorts such as Memorial Sloan Kettering--Integrated Mutation Proﬁling of Actionable Cancer Targets (MSK-IMPACT), Foundation Medicine (FM), which are found at a frequency of 0.05% to 0.13% in the MSK-IMPACT and FM cohorts.[@cit0006] *EGFR*-*RAD51* is the most common type of *EGFR* fusions. It is oncogenic, able to mediate downstream signaling through the MAPK and PI3K/AKT pathways and can be therapeutically targeted with available EGFR-TKIs.[@cit0004] Other *EGFR* fusion partner genes have also been reported, including *PURB*, *TNS3*, *ZCCHC6* and *SEPTIN14* in NSCLC.[@cit0003]--[@cit0006] In this case, we provided the ﬁrst report of a patient with the fusion of *KIF5B* exon15 to *EGFR* exon 18 in a primary lung adenocarcinoma through NGS. She responded well to treatment with afatinib and bevacizumab.

We identified the novel *KIF5B*-*EGFR* rearrangement through NGS. Traditional methods for detection of *EGFR* fusion have limitations. Immunohistochemistry and fluorescence in situ hybridization depend on diagnostic expertise, and reverse-transcriptase polymerase chain reaction is unable to detect novel chromosomal rearrangements. Compared with traditional methods, NGS allows for multiplex testing and enables the detection of known as well as uncommon genomic events. More and more rare or atypical *EGFR* mutations have been identified through NGS.

*KIF5B* is located on the short arm of human chromosome 10 and encodes member 5B of the kinesin family of proteins. Its product is a component of a motor protein complex that is associated with microtubules and mediates the transport of organelles within eukaryotic cells.[@cit0007] There is currently no report on *KIF5B*-*EGFR*. In this case, we provided the ﬁrst report of a patient with the fusion of *KIF5B* exon15 to *EGFR* exon 18 that contains the EGFR tyrosine kinase domain in a primary lung adenocarcinoma. Konduri et al described five patients with metastatic lung cancer whose tumors harbored *EGFR* fusions and verified that Ba/F3 cells expressing *EGFR*-*RAD51* were sensitive to different first-third generation EGFR-TKI drugs in vitro.[@cit0004] Afatinib is an irreversible inhibitor of the ErbB family that is expected to inhibit tumors with activating *EGFR* mutations more strongly than are reversible EGFR-TKIs. Several clinical trials have shown favorable PFS with acceptable toxicity proﬁles for combination therapy consisting of bevacizumab and EGFR-TKIs in untreated *EGFR*-mutant tumors.[@cit0008]--[@cit0010] In consideration of the synergistic effects of afatinib and bevacizumab, we experimentally treated the *KIF5B*-*EGFR* patient with afatinib and bevacizumab. The patient exhibited a significant partial response after treatment with afatinib and bevacizumab for 2 months.

It is worth noting that in this patient, although the lesion progressed after treatments of moxifloxacin and voriconazole, co-infection cannot be ruled out absolutely. Besides, the possibility of delayed absorption of lung infiltrations caused by fungal infection should not be neglected. In addition, the favorable response of the patient to anti-tumor therapy should be attributed to the combined effects of afatinib and bevacizumab. We did not explore the mechanism of EGFR-TKI on this new target, which can be a direction for future efforts.

Conclusion {#s0004}
==========

In the present case, the patient of lung adenocarcinoma with *KIF5B*-*EGFR* fusion achieved a remarkable remission from treatment with EGFR-TKIs and the monoclonal antibody to vascular endothelial growth factor A. We provided case experiences supporting the use of afatinib and bevacizumab for treatment of the patients with NSCLC who are harboring *KIF5B*-*EGFR* fusion.
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